INOVIO Cash and Short-term Investments Drop to $58.5M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy INO?
Cash, cash equivalents and short-term investments were $58.5M vs. $94.1M as of December 31, 2024. "With our first BLA now under review by the FDA, we are focused on delivering INO-3107 to RRP patients who are desperate for treatment options that reduce reliance on surgery to control this rare and devastating disease," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "Our top priority is advancing INO-3107, and to do so, optimizing and extending our financial resources towards our target PDUFA date of October 30, 2026. We are excited about the opportunities ahead as we prepare to become a commercial-stage company and work to leverage the power of partnerships to advance other promising candidates in our pipeline. I look forward to providing more updates on our progress with these efforts in the coming months."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.670
Low
3.00
Averages
7.33
High
13.00
Current: 1.670
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals in the Eastern District of Pennsylvania on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: Throughout the class period, Inovio was accused of making materially false and misleading statements regarding the manufacturing capabilities of its CELLECTRA device, which were claimed to support the FDA's accelerated approval for INO-3107, while in reality, production deficiencies led to delays.
- Stock Price Volatility: Following the release of its financial results on August 9, 2024, Inovio's stock price fell by 3.1% to $8.44 per share due to the announcement of a delay in submitting the INO-3107 BLA until mid-2025; on December 29, 2025, the stock plummeted 24.45% to $1.73 per share after the FDA accepted the BLA for standard review instead of accelerated.
- Severe Legal Consequences: The class action lawsuit could result in significant financial liabilities for Inovio, potentially impacting its future fundraising capabilities and market credibility, thereby hindering its commercialization efforts in the biotechnology sector.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period regarding deficiencies in its CELLECTRA device and overstated the prospects of its INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its strong track record in this field.
- Investor Guidance: Investors are advised to select qualified counsel with proven success in securities litigation, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their legal rights.
- BlackRock TCP Capital: During the period from November 6, 2024, to January 23, 2026, the lawsuit alleges that the company failed to timely and appropriately value its investments, leading to understated unrealized losses and overstated net asset value, which misled investors in their decision-making.
- Oracle Corporation: From June 12, 2025, to December 16, 2025, the lawsuit claims that Oracle's AI infrastructure strategy resulted in massive capital expenditure increases without corresponding revenue growth, heightening the company's debt risks and impacting its financial stability.
- Paysafe and Inovio: Paysafe faces allegations during the period from March 4, 2025, to November 12, 2025, for failing to disclose significant reliance on high-risk clients, potentially negatively impacting revenue growth; meanwhile, Inovio is accused of manufacturing deficiencies from October 10, 2023, to December 26, 2025, which may affect the timeliness and success of its FDA application.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegation: The complaint alleges that Inovio suffered from manufacturing deficiencies related to its CELLECTRA device and is unlikely to file the INO-3107 Biologics License Application (BLA) by the second half of 2024, rendering the company's public statements throughout the class period false and misleading.
- Investor Losses: As the market became aware of the truth regarding Inovio, investors suffered damages, prompting the Schall Law Firm to encourage affected investors to join the lawsuit to recover losses, highlighting significant deficiencies in the company's transparency and compliance.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and urges affected shareholders to take action before class certification to ensure their rights are protected, reflecting a commitment to safeguarding investor interests.
See More
Inovio Pharmaceuticals Securities Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the Class Period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device and the overstated prospects of the INO-3107 Biologics License Application, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first for the number of securities class action settlements in 2017, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action process.
See More
Faruqi & Faruqi Investigates Inovio Investor Claims
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Inovio Pharmaceuticals for potential claims from investors who purchased securities between October 10, 2023, and December 26, 2025, indicating a focus on the company's future legal risks.
- Investor Rights Reminder: The firm reminds investors that April 7, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the importance and urgency of investor participation in legal proceedings.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers to enhance accessibility and confidence in legal support for investors.
- Potential Impact Assessment: This investigation could negatively affect Inovio's stock price and market confidence, prompting investors to monitor legal developments closely to adjust their investment strategies accordingly.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals in the Eastern District of Pennsylvania on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: Throughout the class period, Inovio was accused of making materially false and misleading statements regarding the manufacturing capabilities of its CELLECTRA device, which were claimed to support the FDA's accelerated approval for INO-3107, while in reality, production deficiencies led to delays.
- Stock Price Volatility: Following the release of its financial results on August 9, 2024, Inovio's stock price fell by 3.1% to $8.44 per share due to the announcement of a delay in submitting the INO-3107 BLA until mid-2025; on December 29, 2025, the stock plummeted 24.45% to $1.73 per share after the FDA accepted the BLA for standard review instead of accelerated.
- Severe Legal Consequences: The class action lawsuit could result in significant financial liabilities for Inovio, potentially impacting its future fundraising capabilities and market credibility, thereby hindering its commercialization efforts in the biotechnology sector.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period regarding deficiencies in its CELLECTRA device and overstated the prospects of its INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its strong track record in this field.
- Investor Guidance: Investors are advised to select qualified counsel with proven success in securities litigation, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their legal rights.
- BlackRock TCP Capital: During the period from November 6, 2024, to January 23, 2026, the lawsuit alleges that the company failed to timely and appropriately value its investments, leading to understated unrealized losses and overstated net asset value, which misled investors in their decision-making.
- Oracle Corporation: From June 12, 2025, to December 16, 2025, the lawsuit claims that Oracle's AI infrastructure strategy resulted in massive capital expenditure increases without corresponding revenue growth, heightening the company's debt risks and impacting its financial stability.
- Paysafe and Inovio: Paysafe faces allegations during the period from March 4, 2025, to November 12, 2025, for failing to disclose significant reliance on high-risk clients, potentially negatively impacting revenue growth; meanwhile, Inovio is accused of manufacturing deficiencies from October 10, 2023, to December 26, 2025, which may affect the timeliness and success of its FDA application.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegation: The complaint alleges that Inovio suffered from manufacturing deficiencies related to its CELLECTRA device and is unlikely to file the INO-3107 Biologics License Application (BLA) by the second half of 2024, rendering the company's public statements throughout the class period false and misleading.
- Investor Losses: As the market became aware of the truth regarding Inovio, investors suffered damages, prompting the Schall Law Firm to encourage affected investors to join the lawsuit to recover losses, highlighting significant deficiencies in the company's transparency and compliance.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and urges affected shareholders to take action before class certification to ensure their rights are protected, reflecting a commitment to safeguarding investor interests.
See More
Inovio Pharmaceuticals Securities Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the Class Period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device and the overstated prospects of the INO-3107 Biologics License Application, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first for the number of securities class action settlements in 2017, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action process.
See More
Faruqi & Faruqi Investigates Inovio Investor Claims
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Inovio Pharmaceuticals for potential claims from investors who purchased securities between October 10, 2023, and December 26, 2025, indicating a focus on the company's future legal risks.
- Investor Rights Reminder: The firm reminds investors that April 7, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the importance and urgency of investor participation in legal proceedings.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers to enhance accessibility and confidence in legal support for investors.
- Potential Impact Assessment: This investigation could negatively affect Inovio's stock price and market confidence, prompting investors to monitor legal developments closely to adjust their investment strategies accordingly.
See More
